Aligos Therapeutics, Inc. may be able to improve on the safety and efficacy for the first drug approved for non-alcoholic/metabolic dysfunction-associated steatohepatitis (NASH/MASH), Madrigal Pharmaceuticals, Inc.’s Rezdiffra (resmetirom), based on Phase IIa data for its THRβ agonist ALG-055009, but Aligos is seeking a partner to advance its drug.
Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear
Aligos’s THRβ agonist yielded hepatic fat reduction equal to or better than its class, but the biotech prefers moving forward with a partner. Hepatitis B may be the firm’s higher priority.
